BioMedNewsBreaks

TuesdayJan 06, 2026 9:20 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at January Investor Conferences

Tonix Pharmaceuticals (NASDAQ: TNXP) announced that its management team will present and host investor meetings at multiple January investor conferences, including the Sachs Associates 9th Annual Neuroscience Innovation Forum and Biotech Showcase 2026, both held in San Francisco. President and Chief Executive Officer Seth Lederman, M.D., is scheduled to deliver a company presentation and participate in a panel discussion focused on neuropsychiatric drug development at the Sachs Associates forum, and to present at Biotech Showcase 2026, with a replay of the presentation expected to be made available on the company’s website following the event. To view the full press release, visit…

Continue Reading

MondayJan 05, 2026 3:56 pm

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Issues Clarification on Prior Reference to LUNR Aerospace 

Fifty 1 Labs (OTC: FITY) issued a clarification regarding its Aug. 26, 2025, press release, confirming that no formal partnership or collaboration has ever been formed between the company, or its former subsidiary Fifty1 AI Labs, and LUNR Aerospace, and that there is no current intent to do so. The company stated that following the resignation of former CEO Mr. Arora on Dec. 1, 2025, there is no common ownership, management, or board representation between the entities, and that Fifty1 Labs divested from Fifty1 AI Labs Inc. as of Dec. 3, 2025. Management emphasized that there is no overlap in work, leadership, funding, or affiliation…

Continue Reading

MondayJan 05, 2026 11:10 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Partners With neurocare Group AG To Build Nationwide Neuroplastic Care Network 

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced a partnership with neurocare Group AG to create a nationwide network of clinics offering integrated neuroplastic care for depression, PTSD, and other serious mental health disorders. The planned model combines transcranial magnetic stimulation with ketamine and other neuroplastic drugs, hyperbaric oxygen therapy, and supportive psychotherapy, building on pilot programs that demonstrated high remission rates among first responders and recent publications reporting strong response and remission in treatment-resistant depression. Leveraging neurocare’s existing and affiliated U.S. clinic footprint and a broad installed base of TMS devices, the partners aim to make integrated neuroplastic therapy accessible nationwide by the end of 2026…

Continue Reading

MondayJan 05, 2026 9:00 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Attend JP Morgan 2026 Annual Healthcare Conference

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place Jan. 12–15, 2026, at the Westin St. Francis Hotel in San Francisco, where Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will be available Jan. 12–14 for off-site meetings with investors and potential commercialization and co-development partners. Discussions are expected to focus on the company’s recently announced 510(k) clearance from the U.S. Food and Drug Administration for its patented, cable-free 12-lead electrocardiogram synthesis software for arrhythmia assessment,…

Continue Reading

WednesdayDec 31, 2025 9:20 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Issues Shareholder Letter Highlighting 2025 Milestones and 2026 Outlook

Nutriband (NASDAQ: NTRB) announced that Chief Executive Officer Gareth Sheridan has published a letter to shareholders outlining key achievements during 2025 and providing perspective on the Company’s priorities and outlook for 2026. The update highlighted Nutriband’s continued focus on shareholder value, including disciplined capital management, a 25% preferred stock dividend issued in 2025, and progress toward reducing share price volatility with the expiration of IPO-era warrants in October 2026. The Company also detailed significant advances for its lead product, AVERSA(TM) Fentanyl, which is being developed as an abuse-deterrent opioid transdermal patch. During 2025, Nutriband strengthened its intellectual property portfolio with…

Continue Reading

MondayDec 29, 2025 10:10 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Sells 90% Stake in Pocono Pharmaceutical for $5 Million

Nutriband (NASDAQ: NTRB) announced that it has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million, while retaining a 10% ownership interest following the transaction. The company said proceeds from the sale will be used to support continued development of AVERSA Fentanyl, a transdermal opioid patch designed to deter abuse, misuse, and accidental exposure, which Nutriband believes has the potential to become the world’s first abuse-deterrent fentanyl patch and generate estimated annual U.S. sales of $80 million to $200 million. To view the full press release, visit https://ibn.fm/rbBzf About Nutriband…

Continue Reading

TuesdayDec 23, 2025 12:58 pm

BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Forms Strategic Consulting Partnership With PBACO Holding

HealthLynked (OTCQB: HLYK) announced a strategic consulting partnership with PBACO Holding LLC, a physician-led, value-based care organization supporting more than 15,000 physicians across 26 states and managing over 400,000 patient lives. The partnership is intended to strengthen HealthLynked’s integration with large insurance payers and accelerate deployment of its AI-enabled care-coordination platform by leveraging PBACO’s expertise in value-based contracting, commercial and government ACO program design, payer relationships, and multi-state provider network operations. To view the full press release, visit https://ibn.fm/wFDcl About HealthLynked Corp. HealthLynked Corp. enhances healthcare through personalized care management that improves outcomes and reduces costs. Its cloud-based platform connects patients with providers for virtual or in-office appointments and consolidates medical records…

Continue Reading

MondayDec 22, 2025 9:46 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens Research Access to PDAOAI Evidence Interrogation Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced it has opened research access to PDAOAI, its proprietary evidence interrogation platform designed to extract biologically meaningful signals from large and complex biomedical datasets without training bespoke large language models on proprietary data. The company is also providing researchers access to a comprehensive TGF beta literature corpus comprising more than 125,000 PubMed abstracts through a dedicated Discord research channel, with the platform developed alongside Oncotelics clinical and preclinical programs to enhance the speed, depth, and efficiency of discovery across its pipeline. To view the full press release, visit https://ibn.fm/U31jX About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the…

Continue Reading

FridayDec 19, 2025 9:33 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs LOI to Explore Quantum-AI Technology Collaboration

Nutriband (NASDAQ: NTRB) announced the signing of a nonbinding letter of intent with the Qvanta Group of Companies to explore potential collaboration involving secure artificial intelligence, advanced computing, and cybersecurity technologies that may support Nutriband’s research and long-term product development initiatives. The company said the discussions will focus on areas such as secure AI and analytics platforms for regulated pharmaceutical data, data integrity frameworks supporting abuse-deterrent technologies, and advanced modeling and simulation enabled by quantum-ready infrastructure, while emphasizing that the LOI does not establish a partnership or commercial relationship and that any future collaboration would be subject to further review, due diligence, and definitive agreements. To…

Continue Reading

ThursdayDec 18, 2025 11:07 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease 

Soligenix (NASDAQ: SNGX) announced that results from its Phase 2a proof-of-concept study evaluating SGX945 (dusquetide) for the treatment of aphthous ulcers associated with Behçet’s Disease have been published in Rheumatology (Oxford), reporting beneficial effects in seven of eight patients with sustained improvement through a four-week follow-up period after treatment ended. The company said outcomes for SGX945, including reductions in oral ulcers and pain and favorable area under the curve measurements, were comparable to those reported in a Phase 3 study of apremilast (Otezla(R)), despite SGX945 dosing stopping at Week 4 while apremilast required continuous administration. Soligenix noted SGX945 was well tolerated with no treatment-related adverse events observed and said it…

Continue Reading